Live Breaking News & Updates on Neuro Pharmaceuticals

Stay updated with breaking news from Neuro pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp-PLA2 Inhibitor Targeting Neurodegenerative and Inflammatory Diseases

SNP318, a novel oral Lp-PLA2 inhibitor optimized for CNS diseases, advances into human clinical trials. Systemic administration of oral Lp-PLA2 inhibitors has. ....

Western Australia , Prnewswire Scineuro Pharmaceuticals , Scineuro Pharmaceuticals , Diabetic Macular , Neuro Pharmaceuticals ,

Secarna Pharmaceuticals and SciNeuro Pharmaceuticals Enter into Research ...

Secarna Pharmaceuticals and SciNeuro Pharmaceuticals Enter into Research . ....

United States , Anne Hennecke Lydia Robinson Garcia , Alexander Gebauer , Planegg Martinsried , Secarna Pharmaceuticals , Mc Services , Secarna Pharmaceuticals Gmbh Co , News Network , Scineuro Pharmaceuticals , Secarna Pharmaceuticals Gmbh , Central Nervous , Central Nervous System , Neuro Pharmaceuticals , Lydia Robinson Garcia ,

Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the

EQS-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): AgreementSecarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the field of CNS diseases 27.03.2023 / 16:04 CET/CESTThe issuer is solely responsible for the content of this announcement. Secarna Pharmaceuti. ....

United States , Anne Hennecke Lydia Robinson Garcia , Alexander Gebauer , Planegg Martinsried , Secarna Pharmaceuticals Gmbh Co , Scineuro Pharmaceuticals , Mc Services , Secarna Pharmaceuticals , Distribution Services , Secarna Pharmaceuticals Gmbh , Central Nervous , Central Nervous System , Neuro Pharmaceuticals , Corporate News , Regulatory Announcements ,

SciNeuro Pharmaceuticals Announces the Appointment of Guojun Bu, Ph.D., as Chief Scientific Officer, and Provides Update on Pipeline of Novel CNS Therapeutics

/PRNewswire/ SciNeuro Pharmaceuticals is developing novel therapeutics to address major unmet need within CNS diseases. The company is pleased to announce. ....

United States , Mary Lowell Leary , Mayo Clinic Neuroregeneration Lab , Mayo Clinic Alzheimer Disease Research Center , Washington University School Of Medicine , Eli Lilly Co , Department Of Neuroscience , Prnewswire Scineuro Pharmaceuticals , American Association For The Advancement Of Science , Alzheimer Association , Scineuro Pharmaceuticals , Mayo Clinic , Alpha Synuclein Inhibitor , Neuro Pharmaceuticals , Chief Scientific , Chief Scientific Officer , Mary Lowell Leary Professor , Associate Director , Mayo Clinic Alzheimer , Disease Research , Cell Biology , Washington University School , Molecular Neurodegeneration , Associate Editor , Science Advances , Advisory Board ,

List: the Top Neuroscience Startups That Raised $100 Million or More

Funding for companies developing drugs for neurological disorders is seeing an uptick. Here are the firms that have raised the most cash to date. ....

United States , New York , Thousand Oaks , San Diego , Alamar Biosciences , Erik Isakson Getty , Cosmo Feilding Mellen , Beckley Psytech , Emalex Biosciences , Lou Gehrig , Kristina Burow , Amanda Feilding , Capsida Biotherapeutics , Adarx Pharmaceuticals , Drug Administration , Beckley Foundation , Opiant Pharmaceuticals , Scineuro Pharmaceuticals , Lexeo Therapeutics , Central Nervous System , Getty Images , Sonoran Desert , Axial Therapeutics , Neuro Pharmaceuticals , Bi Prime , Mental Health ,